The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy. ABBOTT ...

Abbott has announced that the US Food and Drug Administration (FDA) has approved the FreeStyle Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to ...

Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to ...

Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin (HbA1c) at three months 1 Reductions in HbA1c ...

A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional ...

In a recent press release from Abbott, they announced FreeStyle® Libre System, the company’s revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having ...

(RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people four years and older ...

The FreeStyle Libre 3 glucose monitoring system (Abbott) has been granted a CE mark for use by people with diabetes in the countries of the European Union (EU). The next-generation FreeStyle Libre 3 ...

SAN FRANCISCO--(BUSINESS WIRE)--Today, Nutrino, (www.nutrino.co) announces the collaboration with the LibreLink 1, 2 application, designed for Abbott’s FreeStyle Libre Flash Glucose Monitoring system.

STATEN ISLAND, N.Y. — Abbott is asking consumers to be cautious when using glucose monitoring systems, due to a potential fire hazard, according to a notice by the U.S. Food and Drug Administration ...

Thursday, Abbott Laboratories (NYSE:ABT) said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.

Abbott is designing a first-of-its-kind biowearable that will enable people with diabetes to continuously monitor glucose and ketones in one sensor Device promises to redefine care for people with ...